메뉴 건너뛰기




Volumn 116, Issue SUPPL. 4, 2010, Pages 1053-1058

Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma

Author keywords

Antiangiogenic therapy; Bevacizumab; Medullary thyroid cancer; Radioimmunotherapy

Indexed keywords

BEVACIZUMAB; CALCITONIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F6 I 131; UNCLASSIFIED DRUG;

EID: 76249125907     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24792     Document Type: Conference Paper
Times cited : (26)

References (35)
  • 1
    • 33644910397 scopus 로고    scopus 로고
    • Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: The European perspective
    • Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective. Cancer Biother Radiopharm. 2006; 21:1-4.
    • (2006) Cancer Biother Radiopharm , vol.21 , pp. 1-4
    • Chatal, J.F.1
  • 2
    • 0036840133 scopus 로고    scopus 로고
    • Radioimmunotherapy of B-cell non-hodgkin's lymphoma: From clinical trials to clinical practice
    • Juweid M. Radioimmunotherapy of B-cell non-hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43:1507-1529.
    • (2002) J Nucl Med , vol.43 , pp. 1507-1529
    • Juweid, M.1
  • 3
    • 0036255688 scopus 로고    scopus 로고
    • Targeted therapy of cancer with radiolabeled antibodies
    • Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;5:693-713.
    • (2002) J Nucl Med , vol.5 , pp. 693-713
    • Goldenberg, D.M.1
  • 4
    • 33846549106 scopus 로고    scopus 로고
    • Advances in cancer therapy with radiolabeled monoclonal antibodies
    • Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 2006;50:248-264.
    • (2006) Q J Nucl Med Mol Imaging , vol.50 , pp. 248-264
    • Goldenberg, D.M.1    Sharkey, R.M.2
  • 5
  • 7
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 8
    • 0028929803 scopus 로고
    • Angiogenesis in cancer, vascular, rheumatoid and other disease
    • Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
    • (1995) Nat Med , vol.1 , pp. 27-31
    • Folkman, J.1
  • 9
    • 0026083903 scopus 로고
    • Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma
    • Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
    • (1991) N Engl J Med , vol.324 , pp. 1-8
    • Weidner, N.1    Semple, J.P.2    Welch, W.R.3    Folkman, J.4
  • 10
    • 0027717345 scopus 로고
    • Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
    • Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
    • (1993) Am J Pathol , vol.143 , pp. 401-409
    • Weidner, N.1    Carroll, P.R.2    Flax, J.3    Blumenfeld, W.4    Folkman, J.5
  • 12
    • 0038626211 scopus 로고    scopus 로고
    • Tumor response to radiotherapy regulated by endothelial cell apoptosis
    • Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155-1159.
    • (2003) Science , vol.300 , pp. 1155-1159
    • Garcia-Barros, M.1    Paris, F.2    Cordon-Cardo, C.3
  • 13
    • 0017183433 scopus 로고
    • Association of medullary carcinoma of the thyroid with carcinoembryonic antigen
    • Ishikawa N, Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br J Cancer. 1976;34:111-115.
    • (1976) Br J Cancer , vol.34 , pp. 111-115
    • Ishikawa, N.1    Hamada, S.2
  • 14
    • 0032898058 scopus 로고    scopus 로고
    • Comparative toxicity and efficacy of 1- and 2-step (bipecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer
    • Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Comparative toxicity and efficacy of 1- and 2-step (bipecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer. J Nucl Med. 1999;40:198-204.
    • (1999) J Nucl Med , vol.40 , pp. 198-204
    • Kraeber-Bodere, F.1    Faivre-Chauvet, A.2    Sai-Maurel, C.3
  • 15
    • 0032697614 scopus 로고    scopus 로고
    • Toxicity and efficacy of radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft: Comparison of iodine-131-labeled F(ab)2 and pretargeted bivalent hapten, and evaluation of repeated injections
    • Kraeber-Bodere F, Faivre-Chauvet, A, Sai-Maurel, C, et al. Toxicity and efficacy of radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft: comparison of iodine-131-labeled F(ab")2 and pretargeted bivalent hapten, and evaluation of repeated injections. Clin Cancer Res. 1999;5:3183s-3189s.
    • (1999) Clin Cancer Res , vol.5
    • Kraeber-Bodere, F.1    Faivre-Chauvet, A.2    Sai-Maurel, C.3
  • 16
    • 0032719527 scopus 로고    scopus 로고
    • Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial
    • Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5:3190s-3198s.
    • (1999) Clin Cancer Res , vol.5
    • Kraeber-Bodere, F.1    Bardet, S.2    Hoefnagel, C.A.3
  • 17
    • 33645834287 scopus 로고    scopus 로고
    • Survival improvement in medullary thyroid carcinoma patients given pretargeted CEA radioimmunotherapy
    • Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in medullary thyroid carcinoma patients given pretargeted CEA radioimmunotherapy. J Clin Oncol. 2006; 24:1705-1711.
    • (2006) J Clin Oncol , vol.24 , pp. 1705-1711
    • Chatal, J.F.1    Campion, L.2    Kraeber-Bodere, F.3
  • 18
    • 0036463694 scopus 로고    scopus 로고
    • Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft
    • Kraeber-Bodere F, Sai-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther. 2002;14:267-274.
    • (2002) Mol Cancer Ther , vol.14 , pp. 267-274
    • Kraeber-Bodere, F.1    Sai-Maurel, C.2    Campion, L.3
  • 19
    • 33644846851 scopus 로고    scopus 로고
    • Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    • Kulke M, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401-406.
    • (2006) J Clin Oncol , vol.24 , pp. 401-406
    • Kulke, M.1    Stuart, K.2    Enzinger, P.C.3
  • 20
    • 0017874586 scopus 로고    scopus 로고
    • Farker PJ, Speck JC. Protein and cell membrane iodination with a springly soluble chloramine; 1,3,4,6 tetrachloro-3a, 6a-diphenyl glycoluryl. Biophys Res Commun. 1978;80: 849-854.
    • Farker PJ, Speck JC. Protein and cell membrane iodination with a springly soluble chloramine; 1,3,4,6 tetrachloro-3a, 6a-diphenyl glycoluryl. Biophys Res Commun. 1978;80: 849-854.
  • 21
    • 22044444554 scopus 로고    scopus 로고
    • Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate
    • Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood. 2005;106:125-134.
    • (2005) Blood , vol.106 , pp. 125-134
    • Yabu, T.1    Tomimoto, H.2    Taguchi, Y.3    Yamaoka, S.4    Igarashi, Y.5    Okazaki, T.6
  • 22
    • 0031906775 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
    • Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998;32:133-138.
    • (1998) Histopathology , vol.32 , pp. 133-138
    • Terris, B.1    Scoazec, J.Y.2    Rubbia, L.3
  • 23
    • 28044447317 scopus 로고    scopus 로고
    • A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETS) [abstract]
    • Abstract 4008
    • Kulke M, Lenz H, Meropol N, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETS) [abstract]. J Clin Oncol. 2005;23(suppl). Abstract 4008.
    • (2005) J Clin Oncol , vol.23 , Issue.SUPPL.
    • Kulke, M.1    Lenz, H.2    Meropol, N.3
  • 24
    • 28044441251 scopus 로고    scopus 로고
    • Improved progression free survival (PFS) and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract]
    • Abstract 4007
    • Yao J, Ng C, Hoff P, et al. Improved progression free survival (PFS) and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract]. J Clin Oncol. 2005;23(suppl). Abstract 4007.
    • (2005) J Clin Oncol , vol.23 , Issue.SUPPL.
    • Yao, J.1    Ng, C.2    Hoff, P.3
  • 25
    • 23544478499 scopus 로고    scopus 로고
    • A phase II study of thalidomide in metastatic neuroendocrine tumors [abstract]
    • Abstract 1931
    • Xu Y, Ellison C, Martin E, et al. A phase II study of thalidomide in metastatic neuroendocrine tumors [abstract]. Proc Am Soc Clin Oncol. 2002;20(suppl). Abstract 1931.
    • (2002) Proc Am Soc Clin Oncol , vol.20 , Issue.SUPPL.
    • Xu, Y.1    Ellison, C.2    Martin, E.3
  • 26
    • 0029892557 scopus 로고    scopus 로고
    • Microvessel count: An indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma
    • Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol. 1996;9:636-641.
    • (1996) Mod Pathol , vol.9 , pp. 636-641
    • Fontanini, G.1    Vignati, S.2    Pacini, F.3    Pollina, L.4    Basolo, F.5
  • 27
    • 33846850223 scopus 로고    scopus 로고
    • Vandetanib (ZD6474): An orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
    • Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs. 2007;16:239-249.
    • (2007) Expert Opin Investig Drugs , vol.16 , pp. 239-249
    • Herbst, R.S.1    Heymach, J.V.2    O'Reilly, M.S.3    Onn, A.4    Ryan, A.J.5
  • 28
    • 0036327411 scopus 로고    scopus 로고
    • Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts
    • Kinuya S, Kawashima A, Yokoyama K, et al. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J Nucl Med. 2002;43:1084-1089.
    • (2002) J Nucl Med , vol.43 , pp. 1084-1089
    • Kinuya, S.1    Kawashima, A.2    Yokoyama, K.3
  • 29
    • 1842847331 scopus 로고    scopus 로고
    • Benefits of combined radioimmunotherapy and antiangiogenic therapy in a liver metastasis model of human colon cancer cells
    • Li XF, Kinuya S, Yokoyama K, et al. Benefits of combined radioimmunotherapy and antiangiogenic therapy in a liver metastasis model of human colon cancer cells. Eur J Nucl Med Mol Imaging. 2002;12:1669-1674.
    • (2002) Eur J Nucl Med Mol Imaging , vol.12 , pp. 1669-1674
    • Li, X.F.1    Kinuya, S.2    Yokoyama, K.3
  • 30
    • 3142712910 scopus 로고    scopus 로고
    • Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy
    • Kinuya S, Yokoyama K, Koshida K, et al. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy. Eur J Nucl Med Mol Imaging. 2004;31:981-985.
    • (2004) Eur J Nucl Med Mol Imaging , vol.31 , pp. 981-985
    • Kinuya, S.1    Yokoyama, K.2    Koshida, K.3
  • 31
    • 0036682030 scopus 로고    scopus 로고
    • Cilengitide targeting of alpha (v) beta integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts
    • Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha (v) beta integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263-4272.
    • (2002) Cancer Res , vol.62 , pp. 4263-4272
    • Burke, P.A.1    DeNardo, S.J.2    Miers, L.A.3    Lamborn, K.R.4    Matzku, S.5    DeNardo, G.L.6
  • 32
    • 0031440905 scopus 로고    scopus 로고
    • Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma
    • DeNardo SJ, Kroger LA, Lamborn KR, et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer. 1997;80:2583-2590.
    • (1997) Cancer , vol.80 , pp. 2583-2590
    • DeNardo, S.J.1    Kroger, L.A.2    Lamborn, K.R.3
  • 33
    • 76249095295 scopus 로고    scopus 로고
    • Toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in mouse model of medullary thyroid carcinoma [abstract]
    • 145P
    • Kraeber-Bodere F, Sai-Maurel C, Faivre-Chauvet A, et al. Toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in mouse model of medullary thyroid carcinoma [abstract]. J Nucl Med. 2005;46:145P.
    • (2005) J Nucl Med , vol.46
    • Kraeber-Bodere, F.1    Sai-Maurel, C.2    Faivre-Chauvet, A.3
  • 34
    • 19944422751 scopus 로고    scopus 로고
    • Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    • Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553-563.
    • (2004) Cancer Cell , vol.6 , pp. 553-563
    • Winkler, F.1    Kozin, S.V.2    Tong, R.T.3
  • 35
    • 0038176480 scopus 로고    scopus 로고
    • Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction
    • Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003;9:1957-1971.
    • (2003) Clin Cancer Res , vol.9 , pp. 1957-1971
    • Wachsberger, P.1    Burd, R.2    Dicker, A.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.